Dedifferentiated leiomyosarcoma of the uterus: a clinicopathologic and immunohistochemical analysis of 23 cases
Histopathology · 2023
DOI: 10.1111/his.14870 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, 2023. Verfasst von David B Chapel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Women's and Perinatal Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Leiomyosarcoma, Smooth Muscle Tumor, Leiomyoma, Uterine Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ovarian Cancer Research Alliance.
Abstract (Originalsprache)
Aims
To morphologically and immunophenotypically characterize dedifferentiated uterine leiomyosarcoma (LMS). Methods and results We identified 23 dedifferentiated uterine LMS, defined as a malignant uterine smooth muscle tumour containing discrete differentiated and dedifferentiated components (i.e. with and without morphologic and immunophenotypic evidence of smooth muscle differentiation, respectively). The differentiated component was leiomyosarcoma in most cases (17/23), though some arose from a leiomyoma ( n = 4) or smooth muscle tumour of uncertain malignant potential ( n = 2). The dedifferentiated tumour component showed noncohesive polygonal cells with moderate to abundant cytoplasm, pleomorphic nuclei with coarse vesicular to smudged chromatin, one or more macronucleoli, frequent multinucleation, and atypical mitoses. Three cases showed heterologous osteosarcomatous or chondrosarcomatous differentiation. Immunohistochemistry revealed alterations characteristic of uterine LMS, including Rb loss (18/19); strong diffuse p16 (17/19); strong diffuse (9/19) or complete absence of (5/19) p53; and ATRX loss (6/16). Compared to a control cohort of uterine LMS without dedifferentiation, dedifferentiated uterine LMS showed significantly shorter disease‐specific (median, 54 versus 20 months; 5‐year DSS, 46% versus 36%; P = 0.04) and disease‐free (median, 31 versus 8 months; 5‐year DFS, 42% versus 8%; P = 0.002) survival. Of 19 dedifferentiated uterine LMS with follow‐up, 12 had died of disease at median 14 (range, 2–73) months; four were alive with disease at 4, 12, 44, and 50 months; and three were alive with no evidence of disease at 56, 109, and 114 months.
Conclusion
Routine prospective recognition of dedifferentiated uterine LMS and distinction from mimics is advocated for accurate prognostication and for further characterisation of these tumours.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Women's and Perinatal Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
- Department of Pathology, University of Michigan - Michigan Medicine, Ann Arbor, MI, USA.
- Unit of Surgical Pathology, S. Chiara Hospital, Trient, Italy.
- Catholic University of Sacred Heart, Rome, Italy.
ORCID-Profile: Gian F Zannoni, Bradley J Quade, Carlos Parra-Herran
Förderung
- Ovarian Cancer Research Alliance
Zitieren
APA
Chapel, D. B., Maccio, L., Bragantini, E., Zannoni, G. F., Quade, B. J., Parra-Herran, C., & Nucci, M. R. (2023). Dedifferentiated leiomyosarcoma of the uterus: a clinicopathologic and immunohistochemical analysis of 23 cases. Histopathology. https://doi.org/10.1111/his.14870
Vancouver
Chapel DB, Maccio L, Bragantini E, Zannoni GF, Quade BJ, Parra-Herran C, et al. Dedifferentiated leiomyosarcoma of the uterus: a clinicopathologic and immunohistochemical analysis of 23 cases. Histopathology. 2023. doi:10.1111/his.14870
BibTeX
@article{Chapel2023,
author = {Chapel, David B and Maccio, Livia and Bragantini, Emma and Zannoni, Gian F and Quade, Bradley J and Parra-Herran, Carlos and Nucci, Marisa R},
title = {Dedifferentiated leiomyosarcoma of the uterus: a clinicopathologic and immunohistochemical analysis of 23 cases},
journal = {Histopathology},
year = {2023},
doi = {10.1111/his.14870}
}
EUVIMED